Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/45782
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDebie, Yana-
dc.contributor.authorGARCIA FOGEDA, Irene-
dc.contributor.authorWILLEM, Lander-
dc.contributor.authorRoelant, Ella-
dc.contributor.authorVerbruggen, Lise-
dc.contributor.authorVanhoutte, Greetje-
dc.contributor.authorCroes, Lieselot-
dc.contributor.authorVulsteke, Christof-
dc.contributor.authorDemey, Wim-
dc.contributor.authorLybaert, Willem-
dc.contributor.authorHanssens, Marianne-
dc.contributor.authorBols, Alain-
dc.contributor.authorVan Ongeval, Johan-
dc.contributor.authorDe Becker, Ann-
dc.contributor.authorJansens, Hilde-
dc.contributor.authorPrenen, Hans-
dc.contributor.authorJanssens , Annelies-
dc.contributor.authorGoossens , Maria E.-
dc.contributor.authorAnguille, Sebastien-
dc.contributor.authorPeeters , Marc-
dc.contributor.authorvan Dam, Peter A.-
dc.contributor.authorHENS, Niel-
dc.contributor.authorABRAMS, Steven-
dc.contributor.authorVandamme, Timon-
dc.date.accessioned2025-04-01T11:01:19Z-
dc.date.available2025-04-01T11:01:19Z-
dc.date.issued2025-
dc.date.submitted2025-03-24T13:17:23Z-
dc.identifier.citationScientific Reports, 15 (1) (Art N° 7858)-
dc.identifier.urihttp://hdl.handle.net/1942/45782-
dc.description.abstractThe level of protection against SARS-CoV-2 breakthrough infections conferred by the presence of anti-S1 SARS-CoV-2 antibodies (IgGs) in cancer patients is still understudied. This work examines the existence of an anti-S1 immunoglobulin G (IgG) -based correlate of protection (CoP) established by prospectively collected observational data about breakthrough infections with different SARS-CoV-2 variants in a large cohort study with vaccinated cancer patients. 760 cancer patients were longitudinally followed-up, starting before first vaccination until six months after second booster. Anti-S1 SARS-CoV-2 IgGs were quantified in serum samples (N = 2958) and breakthrough infections were monitored using questionnaires, routine COVID-19 testing and medical chart review. A Generalized Estimating Equations approach was used to model the binary infection status as endpoint in relation to anti-S1 IgG titers. It is observed that higher anti-S1 IgG titers correspond to a lower probability of breakthrough infection. For the early pandemic phase, a protective anti-S1 IgG titer above 20.42 BAU/mL was observed. However, with the emergence of the Omicron variant, higher anti-S1 IgG titers are required to be protective, but no clear CoP could be identified.-
dc.description.sponsorshipWe are grateful to the BelCoVac consortium for data sharing and scientific contribution to the project. We kindly thank the B-VOICE, Tri-VOICE plus and REAL-V participants for study participation, the staff members of the Biobank Antwerp and all recruiting physicians. We are thankful to Siddharth Chhajlani, Sven De Keersmaecker, Silke Raats, Isolde Van der Massen, Lisa Verheggen and Sanne Wouters for logistic support and coordination. We wish to acknowledge Kim Claes for the prompt and efficient set-up of the online questionnaires. In addition, we thank the B-VOICE, Tri-VOICE plus and REAL-V study teams from all recruiting centers for patient inclusion and sample collection and the clinical biology study team for performing serological analysis. This work was supported by the Belgian Government through Sciensano (Grant Nos. COVID-19_SC004, COVID-19_SC059, COVID-19_SC061) and Kom op tegen Kanker (KOTK_UZA/2020/12604/1). T. Vandamme is holder of Senior Clinical Investigator Grant 1803723 N of the Research Foundation - Flanders (Belgium) (FWO).-
dc.language.isoen-
dc.publisherNATURE PORTFOLIO-
dc.rightsThe Author(s) 2025. This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommo ns.org/licenses/by-nc-nd/4.0/.-
dc.subject.otherSARS-CoV-2-
dc.subject.otherCOVID-19-
dc.subject.otherCancer patients-
dc.subject.otherCorrelate of protectionCOVID-19 vaccination-
dc.subject.otherAntibodies-
dc.subject.otherBreakthrough infection-
dc.titleCracking the code of a correlate of protection against SARS-CoV-2 breakthrough infection in cancer patients-
dc.typeJournal Contribution-
dc.identifier.issue1-
dc.identifier.volume15-
local.format.pages15-
local.bibliographicCitation.jcatA1-
dc.description.notesVandamme, T (corresponding author), Antwerp Univ Hosp, Multidisciplinary Oncol Ctr Antwerp MOCA, Drie Eikenstr 655, B-2650 Edegem, Belgium.; Vandamme, T (corresponding author), Univ Antwerp, Ctr Oncol Res CORE, Integrated Personalized & Precis Oncol Network IP, Univ Pl 1, B-2610 Antwerp, Belgium.-
dc.description.notesTimon.vandamme@uza.be-
local.publisher.placeHEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY-
local.type.refereedRefereed-
local.type.specifiedArticle-
local.bibliographicCitation.artnr7858-
dc.identifier.doi10.1038/s41598-025-92254-8-
dc.identifier.pmid40050359-
dc.identifier.isi001439684400010-
dc.contributor.orcidVulsteke, Christof/0000-0002-4607-5660-
local.provider.typewosris-
local.description.affiliation[Debie, Yana; Verbruggen, Lise; Vanhoutte, Greetje; Croes, Lieselot; Janssens, Annelies; Prenen, Hans; Anguille, Sebastien; Peeters, Marc; van Dam, Peter A.; Vandamme, Timon] Antwerp Univ Hosp, Multidisciplinary Oncol Ctr Antwerp MOCA, Drie Eikenstr 655, B-2650 Edegem, Belgium.-
local.description.affiliation[Debie, Yana; Croes, Lieselot; Vulsteke, Christof; Janssens, Annelies; Prenen, Hans; Peeters, Marc; van Dam, Peter A.; Vandamme, Timon] Univ Antwerp, Ctr Oncol Res CORE, Integrated Personalized & Precis Oncol Network IP, Univ Pl 1, B-2610 Antwerp, Belgium.-
local.description.affiliation[Garcia-Fogeda, Irene; Hens, Niel] Univ Antwerp, Ctr Hlth Econ Res & Modelling Infect Dis CHERMID, Univ Pl 1, B-2610 Antwerp, Belgium.-
local.description.affiliation[Willem, Lander; Abrams, Steven] Univ Antwerp, Family Med & Populat Hlth FAMPOP, Doornstr 331, B-2610 Antwerp, Belgium.-
local.description.affiliation[Roelant, Ella] Antwerp Univ Hosp, Clin Trial Ctr CTC, Drie Eikenstr 655, B-2650 Edegem, Belgium.-
local.description.affiliation[Vulsteke, Christof] AZ Maria Middelares, GeIntegreerd Kankercentrum Gent IKG, Buitenring Sint Denijs 30, B-9000 Ghent, Belgium.-
local.description.affiliation[Demey, Wim] AZ Klina, Dept Med & Digest Oncol, Augustijnslei 100, B-2930 Brasschaat, Belgium.-
local.description.affiliation[Lybaert, Willem] VITAZ, Dept Med & Digest Oncol, Moerlandstr 1, B-9100 St Niklaas, Belgium.-
local.description.affiliation[Hanssens, Marianne] AZ Groeninge, Kankercentrum Med Oncol, President Kennedylaan 4, B-8500 Kortrijk, Belgium.-
local.description.affiliation[Bols, Alain] Oncol Dept, AZ Sint Jan Brugge, Ruddershove 10, B-8000 Brugge, Belgium.-
local.description.affiliation[Van Ongeval, Johan] AZ Sint Lucas Gent, Dept Gastroenterol & Digest Oncol, Groenebriel 1, B-9000 Ghent, Belgium.-
local.description.affiliation[De Becker, Ann] Univ Ziekenhuis Brussel, Dept Neurol, Laarbeeklaan 101, B-1090 Brussels, Belgium.-
local.description.affiliation[Jansens, Hilde] Antwerp Univ Hosp, Dept Med Oncol, Drie Eikenstr 655, B-2650 Edegem, Belgium.-
local.description.affiliation[Goossens, Maria E.] Sciensano, SD Infect Dis Humans Platform Intervent Studies, Rue Juliette Wytsmanstr 14, B-1050 Brussels, Belgium.-
local.description.affiliation[Anguille, Sebastien] Antwerp Univ Hosp, Dept Otorhinolaryngol, Drie Eikenstr 655, B-2650 Edegem, Belgium.-
local.description.affiliation[Hens, Niel; Abrams, Steven] UHasselt, Data Sci Inst, Interuniv Inst Biostat & Stat Bioinformat, Martelarenlaan 42, B-3500 Hasselt, Belgium.-
local.uhasselt.internationalno-
item.fullcitationDebie, Yana; GARCIA FOGEDA, Irene; WILLEM, Lander; Roelant, Ella; Verbruggen, Lise; Vanhoutte, Greetje; Croes, Lieselot; Vulsteke, Christof; Demey, Wim; Lybaert, Willem; Hanssens, Marianne; Bols, Alain; Van Ongeval, Johan; De Becker, Ann; Jansens, Hilde; Prenen, Hans; Janssens , Annelies; Goossens , Maria E.; Anguille, Sebastien; Peeters , Marc; van Dam, Peter A.; HENS, Niel; ABRAMS, Steven & Vandamme, Timon (2025) Cracking the code of a correlate of protection against SARS-CoV-2 breakthrough infection in cancer patients. In: Scientific Reports, 15 (1) (Art N° 7858).-
item.contributorDebie, Yana-
item.contributorGARCIA FOGEDA, Irene-
item.contributorWILLEM, Lander-
item.contributorRoelant, Ella-
item.contributorVerbruggen, Lise-
item.contributorVanhoutte, Greetje-
item.contributorCroes, Lieselot-
item.contributorVulsteke, Christof-
item.contributorDemey, Wim-
item.contributorLybaert, Willem-
item.contributorHanssens, Marianne-
item.contributorBols, Alain-
item.contributorVan Ongeval, Johan-
item.contributorDe Becker, Ann-
item.contributorJansens, Hilde-
item.contributorPrenen, Hans-
item.contributorJanssens , Annelies-
item.contributorGoossens , Maria E.-
item.contributorAnguille, Sebastien-
item.contributorPeeters , Marc-
item.contributorvan Dam, Peter A.-
item.contributorHENS, Niel-
item.contributorABRAMS, Steven-
item.contributorVandamme, Timon-
item.fulltextWith Fulltext-
item.accessRightsOpen Access-
crisitem.journal.issn2045-2322-
crisitem.journal.eissn2045-2322-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
s41598-025-92254-8.pdfPublished version2.79 MBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.